The nucleic acid isolation and purification market is poised for substantial growth driven by the rise in next-gen sequencing ...

Discover the leading players and innovations shaping the global biosensors market with the "Biosensors Companies Quadrant" report by 360 Quadrants. This comprehensive industry analysis evaluates over ...

Chinese biotech companies, led by Frontier Biotechnologies, signed major cross-border licensing deals in 2026 focused on small nucleic acid (siRNA) drugs, with deals totaling over $36 billion in 2025.

CERS’ INTERCEPT platform (kits + illuminators) is scaling globally, with record 2025 results. They’ve also grown their ...

Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on ...

Arbutus and Genevant's complaint claimed that Moderna's mRNA-based Spikevax shot used lipid nanoparticle (LNP) delivery technology, which enables the safe and effective delivery of nucleic acid ...

AIM-listed specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, has promoted ...

Amid growing concerns over complications arising from blood transfusions and recent cases where children reportedly contracted HIV through contaminated blood, the Supreme Court ...

The global biopharmaceuticals market is projected to grow at a compound annual growth rate (CAGR) of approximately 12% over the next five years. Key factors driving this growth include the rising ...

Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable ...

Structural nanomedicine — what helped give us the COVID vaccine — may now be the key to a potent blood cancer treatment that’s had remarkable early results.

Researchers at Vilnius University (Lithuania) have uncovered how the bacterial protein Cas9, better known as the CRISPR-Cas ...